- Home
- LFT vs MGNX Comparison
LFT vs MGNX Comparison
Compare LFT & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFT
- MGNX
- Stock Information
- Founded
- LFT 2012
- MGNX 2000
- Country
- LFT United States
- MGNX United States
- Employees
- LFT N/A
- MGNX N/A
- Industry
- LFT Real Estate Investment Trusts
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- LFT Real Estate
- MGNX Health Care
- Exchange
- LFT Nasdaq
- MGNX Nasdaq
- Market Cap
- LFT 82.2M
- MGNX 94.9M
- IPO Year
- LFT N/A
- MGNX 2013
- Fundamental
- Price
- LFT $1.62
- MGNX $1.50
- Analyst Decision
- LFT Hold
- MGNX Hold
- Analyst Count
- LFT 1
- MGNX 5
- Target Price
- LFT N/A
- MGNX $3.20
- AVG Volume (30 Days)
- LFT 224.7K
- MGNX 887.6K
- Earning Date
- LFT 11-12-2025
- MGNX 11-12-2025
- Dividend Yield
- LFT 10.06%
- MGNX N/A
- EPS Growth
- LFT N/A
- MGNX N/A
- EPS
- LFT 0.09
- MGNX N/A
- Revenue
- LFT $21,708,246.00
- MGNX $127,626,000.00
- Revenue This Year
- LFT $124.75
- MGNX N/A
- Revenue Next Year
- LFT N/A
- MGNX N/A
- P/E Ratio
- LFT $16.89
- MGNX N/A
- Revenue Growth
- LFT N/A
- MGNX N/A
- 52 Week Low
- LFT $1.42
- MGNX $0.99
- 52 Week High
- LFT $2.84
- MGNX $3.77
- Technical
- Relative Strength Index (RSI)
- LFT 52.09
- MGNX 46.92
- Support Level
- LFT $1.42
- MGNX $1.33
- Resistance Level
- LFT $1.56
- MGNX $1.64
- Average True Range (ATR)
- LFT 0.06
- MGNX 0.11
- MACD
- LFT 0.03
- MGNX 0.00
- Stochastic Oscillator
- LFT 95.00
- MGNX 42.70
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.